Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1176-1180

  Echigo, Ryosuke ^a   Sugimoto, Naotoshi ^a   Yachie, Akihiro ^a   Ohno Shosaku, Takako ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cannabinoid; Cannabinoid receptor 1; Cell growth; Nuclear factor B; Peptidoglycan

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDOGLYCAN; UNCLASSIFIED DRUG; WIN 55 212 2;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ARACHIDONIC ACIDS; BENZOXAZINES; CANNABINOIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCANNABINOIDS; GLIOMA; GLYCERIDES; HUMANS; MORPHOLINES; NAPHTHALENES; NF-KAPPA B; PEPTIDOGLYCAN; PHOSPHORYLATION; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84866466042     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1937     Document Type: Article

References (20)

1. Takeda K and Akira S: TLR signaling pathways. Semin Immunol 16: 3-9, 2004. (Pubitemid 38147427)
2. Buchanan MM, Hutchinson M, Watkins LR and Yin H: Toll-like receptor 4 in CNS pathologies. J Neurochem 114: 13-27, 2010.
3. Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615-1630, 2011.
4. Basseres DS and Baldwin AS: Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830, 2006. (Pubitemid 44657854)
5. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
6. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F and Fernandez-Luna JL: The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2: 646-653, 2011.
7. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M and Watanabe M: Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380, 2009.
8. Guindon J and Hohmann AG: The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 1447-1463, 2011.
9. Centonze D, Finazzi-Agro A, Bernardi G and Maccarrone M: The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28: 180-187, 2007. (Pubitemid 46483718)
10. Cabral GA and Griffin-Thomas L: Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets 8: 159-172, 2008.
11. Saito T, Sugimoto N, Ohta K, Shimizu T, Ohtani K, Nakayama Y, Nakamura T, Hitomi Y, Nakamura H, Koizumi S and Yachie A: Phosphodiesterase inhibitors suppress Lactobacillus casei cell wall-induced NF-κB and MAPK activations and cell proliferation through protein kinase A- or exchange protein activated by cAMP-dependent signal pathway. ScientificWorldJournal 2012: 748572.
12. Klein TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411, 2005.
13. Guzman M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745-755, 2003.
14. Sarfaraz S, Adhami VM, Syed DN, Afaq F and Mukhtar H: Cannabinoids for cancer treatment: progress and promise. Cancer Res 68: 339-342, 2008. (Pubitemid 351380057)
15. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004.
16. Prasad S, Ravindran J and Aggarwal BB: NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336: 25-37, 2010.
17. Jeon YJ, Yang KH, Pulaski JT and Kaminski NE: Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappaB/Rel activation. Mol Pharmacol 50: 334-341, 1996. (Pubitemid 26265138)
18. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R and Vogel Z: Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285: 1616-1626, 2010.
19. Zhang J and Chen C: Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 283: 22601-22611, 2008.
20. Du H, Chen X, Zhang J and Chen C: Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br J Pharmacol 163: 1533-1549, 2011.